Clinical Trial Update: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 clinical trial evaluating Moderna's mRNA-1647 vaccine for cytomegalovirus in healthy participants aged 9 to 25, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• mRNA-1647 (Cytomegalovirus vaccine (mRNA-1647))

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Cytomegalovirus | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING